The slight loss in
bone mineral
density associated with HIV pre-exposure prophylaxis (
PrEP) antiretroviral use is reversible in young adult patients who stop taking the drugs, according to findings presented by researchers today at the 23rd Conference
on Retroviruses and Opportunistic Infections (CROI) in Boston.